side-area-logo

News and Events

Eloxx Pharmaceuticals Chairman and CEO Robert Ward to Participate in a Panel Discussion at the Biotech Showcase 2018 Conference

Eloxx Pharmaceuticals, Inc. (“Eloxx”) (OTC:SVOND) today announced that Robert (“Bob”) Ward will participate in a panel entitled “What it Means to be in the Era of Cures” on Tuesday, January…

Eloxx Pharmaceuticals Appoints Robert Ward Chairman and Chief Executive Officer

Biopharmaceutical Industry Leader with Extensive Experience In Drug Development, Strategic Business Combinations and Commercialization to Lead The Company’s Strategy, Vision and Execution

Eloxx Pharmaceuticals Completes Acquisition Transaction with Sevion Therapeutics

Waltham, MA, Rehovot, Israel, and San Diego, CA – Eloxx Pharmaceuticals Ltd. (“Eloxx”) and Sevion Therapeutics, Inc. (OTCQB: SVON) (“Sevion”) today announced the two companies have completed their previously announced

Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial

Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel translational read-through inducing drugs (TRIDs) for genetic diseases caused by nonsense mutations, announced today dosing of…

Eloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in Europe

Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd.,, today announced that the European Patent Office (EPO) has granted a patent covering the Company's lead product candidate, ELX-02, as well as…

Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer

Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel small molecule medicines for genetic diseases caused by nonsense mutations, today announced the appointment of Gregory…

Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases

Sevion Therapeutics, Inc. (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage biopharmaceutical company developing therapeutics for genetic diseases caused by nonsense mutations, today announced the expansion of its development…

Eloxx Pharmaceuticals Secures US$8 Million Investment from LSP, Increasing Total Raised in Series C to US$38 million

Sevion Therapeutics, Inc. (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, announced today the closing of additional US$8 million…

Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis

Today, Korea Investment Partners (KIP), DSC Investments, Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, announce a…